What did Infratil Limited announce?
Infratil Limited (NZX: IFT) filed “CDC Independent Valuation – 30 September 2026” with NZX on 6 October 2026, as a market update announcement.
- Which company?
- Infratil Limited (NZX: IFT)
- When was it filed?
- 6 October 2026
- Where is the original?
- NZX announcement
CDC Independent Valuation – 30 September 2026
Infratil Limited 5 Market Lane, PO Box 320, Wellington, New Zealand Tel +64-4-473 3663 www.infratil.com
7 October 2026
CDC Independent Valuation – 30 September 2026
CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30
September 2026. Continued progress in customer contracting and the development of CDC’s
capacity pipeline was offset by the macroeconomic impact of a material increase in the forward
yield curve, resulting in higher assumed interest costs over the forecast period.
The valuation decreased by A$78 million from 30 June 2026 to A$18.45 billion, reflecting the
mid-point of the assessed valuation range of A$17.4 billion to A$19.6 billion. Infratil’s 49.69%
interest in CDC is valued at A$9,168 million, down A$45 million from A$9,213 million at 30 June
2026, which reflected Infratil’s interest of 49.72%.
Further valuation details are included in the attached presentation document.
Enquiries should be directed to:
Brett Jackson
Investor Relations
Email: brett.jackson@infratil.com
Authorised for release by:
Matthew Ross
Infratil Chief Financial Officer
---
CDC
INDEPENDENT
VALUATION
30 SEPTEMBER
2026
•CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026.
•Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by the macroeconomic impactof a material
increase in the forward yield curve, resulting in higher assumed interest costs over the forecast period.
–The valuation decreased by A$78 million from 30 June 2026 to A$18.45 billion, reflecting the mid-point of the assessed valuationrange of
A$17.4 billion to A$19.6 billion.
–Infratil’s49.69% interest in CDC is valued at A$9,168 million, down A$45 million from A$9,213 million at 30 June 2026, which reflected Infratil’s
interest of 49.72%.
•The key drivers of the movement in the independent valuation this quarter were:
–Contracted capacity increased to 1.1 GW with a further 70 MW contracted, acceleration of the build programme at various locations, and a 240
MW increase in CDC’s total reported pipeline to 4.2 GW.
–These positive cash flow movements were offset by a material increase in the forward yield curve, which drove forecast debt servicing costs
within the cash flows, and resulted in higher assumed interest costs over the forecast period.
•The independent valuer assessed that the cost of equity increased from 12.45% to 12.58% during the quarter, driven by:
–An increase in the forecast long-term gearing ratio.
–The risk-free rate used in the discount rate is a long-term benchmark and was unchanged at 4.25%.
–This was partly offset by a minor decrease in the asset-specific risk premium associated with continued progress in constructionand
development activity.
•Net debt increased by A$1,161 million over the quarter. Separately, CDC raised A$1.7 billion in debt, including A$700 million in Australian Medium-
Term Notes and A$1 billion through a US Private Placement.
CDC Independent Valuation Update –30 September 2026
1
Valuation Methodology30 September 202630 June 2026
Primary valuation methodologyDCF using FCFE
(with a cross check to market multiples and precedent
transactions)
DCF using FCFE
(with a cross check to market multiples and precedent
transactions)
Terminal year20552055
Enterprise valueA$25,587 millionA$24,504 million
Equity valueA$18,450 millionA$18,528 million
Equity value(Infratil share)A$9,168 million (49.69%)A$9,213 million (49.72%)
Net debt
Including accrued Management Share payments
A$7,137 millionA$5,976 million
Key valuation assumptions
Risk free rate4.25%4.25%
Asset beta0.5750.575
Cost of equity (blended rate)
Reflects the assessed risk of the spectrum of CDC’s
portfolio, from operating data centres with contracted
revenues through to development projects without
contracted revenues.
12.58% (+0.13%)12.45%
Long term EBITDA margin83% (2055)83% (2055)
Capex
Valuation assumes no development beyond
2040
Valuation assumes no development beyond
2040
Independent Valuation Assumptions
2
460
550550
400
810810
1,740
2,580
2,820
0
1,000
2,000
3,000
4,000
Mar-26Jun-26Sep-26
CDC Capacity Pipeline (MW), rounded
1
OperatingUnder constructionFuture build
•Leasable operating and under construction capacity remained unchanged
this quarter as development continued across multiple sites.
•Australian future build capacity increased by 240MW to 2.7GW, reflecting
continued expansion of CDC’s longer-term pipeline to meet strong customer
demand.
•CDC is exploring a number of potentialprojects in Australia and New
Zealand which may be included in the pipeline in the future, subject to
progress against project milestones.
CDC Development Pipeline
Notes: (1) Leasable capacity to FY40, rounded to the nearest 10MW.
3
Leasable Capacity Pipeline
by Region, rounded
1
(MW)
September 2026June 2026
Operating capacity
ACT120120
NSW220220
VIC130130
NZ8080
Total550550
Under construction capacity
ACT--
NSW560560
VIC230230
Other AUS2020
NZ--
Total810810
Future build capacity
AUS2,7302,490
NZ9090
Total2,8202,580
Total Capacity Pipeline4,1803,940
2,600
3,9404,180
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- KFL — Kingfish Limited: KFL – November 2026 monthly update2026-11-16
“1 A WORD FROM THE MANAGER The Kingfish portfolio gross performance return and adjusted NAV return in October were both -1.3%, versus the New Zealand shares benchmark S&P/NZX 50 return of -0.3%. Portfolio Auckland Airport (+1%) reiterated its earnings guidance for underlying…”
- KFL — Kingfish Limited: KFL – August 2026 monthly update2026-08-16
“1 A WORD FROM THE MANAGER The Kingfish portfolio gross performance return and adjusted NAV return in July were +0.7% and +0.6% respectively, versus the New Zealand shares benchmark S&P/NZX 50 return of +0.6%. a2 Milk (-6%) provided an update which confirmed next month it will…”